Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Allergan PLC, consolidated balance sheet: assets

US$ in thousands

	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Cash and cash equivalents	2,503,300)	880,400)	1,817,200)	1,724,000)	1,096,000)
Short-term investments	3,411,600)	1,026,900)	2,814,400)	8,062,300)	9,300)
Teva shares	—)	—)	1,817,700)	3,439,200)	—)
Marketable securities	3,411,600)	1,026,900)	4,632,100)	11,501,500)	9,300)
Accounts receivable, net	3,192,300)	2,868,100)	2,899,000)	2,531,000)	2,401,600)
Inventories	1,133,100)	846,900)	904,500)	718,000)	1,009,700)
Current assets held for sale	—)	34,000)	—)	—)	3,540,300)
Prepaid taxes	437,700)	403,800)	690,900)	957,400)	240,500)
Prepaid insurance	11,500)	16,700)	20,900)	25,700)	24,100)
Contingent income	83,600)	67,700)	80,100)	94,300)	13,800)
Sales and marketing	65,000)	41,800)	31,900)	42,500)	36,700)
Other	288,600)	289,100)	300,100)	263,500)	243,400)
Prepaid expenses and other current assets	886,400)	819,100)	1,123,900)	1,383,400)	558,500)
Current assets	11,126,700)	6,475,400)	11,376,700)	17,857,900)	8,615,400)
Property, plant and equipment, net	1,926,500)	1,787,000)	1,785,400)	1,611,300)	1,573,900)
Right of use asset, operating leases	490,400)	—)	—)	—)	—)
Deferred executive compensation investments	89,200)	90,800)	112,400)	111,700)	118,100)
Equity method investments	7,600)	8,400)	11,500)	12,800)	17,300)
Cost method investments	—)	—)	—)	15,000)	16,700)
Other long-term investments	63,300)	37,600)	60,800)	67,200)	78,200)
Taxes receivable	41,200)	1,674,800)	32,100)	36,000)	39,600)
Contingent income	51,800)	75,300)	—)	—)	—)
Other assets	154,900)	83,700)	51,100)	39,400)	307,500)
Investments and other assets	408,000)	1,970,600)	267,900)	282,100)	577,400)
Non current assets held for sale	31,700)	882,200)	81,600)	27,000)	10,541,300)
Deferred tax assets	576,900)	1,063,700)	319,100)	233,300)	49,500)
Product rights and other intangibles	37,890,600)	43,695,400)	54,648,300)	62,618,600)	67,931,700)
Goodwill	42,248,300)	45,913,300)	49,862,900)	46,356,100)	46,551,500)
Non current assets	83,572,400)	95,312,200)	106,965,200)	111,128,400)	127,225,300)
Total assets	94,699,100)	101,787,600)	118,341,900)	128,986,300)	135,840,700)

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Allergan PLC current assets decreased from 2017 to 2018 but then increased from 2018 to 2019 not reaching 2017 level.
Property, plant and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Allergan PLC property, plant and equipment, net increased from 2017 to 2018 and from 2018 to 2019.
Non current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Allergan PLC non current assets decreased from 2017 to 2018 and from 2018 to 2019.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Allergan PLC total assets decreased from 2017 to 2018 and from 2018 to 2019.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Allergan PLC cash and cash equivalents decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Marketable securities	Amount of investment in marketable security, classified as current.	Allergan PLC marketable securities decreased from 2017 to 2018 but then increased from 2018 to 2019 not reaching 2017 level.
Accounts receivable, net	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Allergan PLC accounts receivable, net decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Allergan PLC inventories decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.

Allergan PLC (NYSE:AGN)

Balance Sheet: Assets

Assets: Selected Items

Current Assets: Selected Items